NASDAQ:STOK Stoke Therapeutics - STOK Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.98 +0.33 (+4.31%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$7.39▼$8.0450-Day Range$7.65▼$9.9852-Week Range$6.88▼$24.97Volume668,352 shsAverage Volume282,496 shsMarket Capitalization$352.32 millionP/E RatioN/ADividend YieldN/APrice Target$24.57 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Stoke Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside207.9% Upside$24.57 Price TargetShort InterestBearish14.71% of Float Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment0.94Based on 2 Articles This WeekInsider TradingSelling Shares$97,205 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.85) to ($3.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector428th out of 995 stocksPharmaceutical Preparations Industry197th out of 482 stocks 4.4 Analyst's Opinion Consensus RatingStoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.57, Stoke Therapeutics has a forecasted upside of 207.9% from its current price of $7.98.Amount of Analyst CoverageStoke Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.71% of the float of Stoke Therapeutics has been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently increased by 1.29%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreStoke Therapeutics has received a 77.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Stoke Therapeutics is -0.59. Previous Next 2.2 News and Social Media Coverage News SentimentStoke Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Stoke Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 3 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $97,205.00 in company stock.Percentage Held by Insiders12.70% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.85) to ($3.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Stoke Therapeutics (NASDAQ:STOK) StockStoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.Read More Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address STOK Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from BrokeragesMarch 17, 2023 | markets.businessinsider.comBank of America Securities Remains a Sell on Stoke Therapeutics (STOK)March 28, 2023 | Tradewins (Ad)Modern Day Options Trading For Beginners!These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. March 15, 2023 | seekingalpha.comStoke gets FDA nod to use higher dose of epilepsy drug in ongoing trialMarch 15, 2023 | finance.yahoo.comStoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet SyndromeMarch 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and Stoke Therapeutics (STOK)March 8, 2023 | msn.com6 Analysts Have This to Say About Stoke TherapeuticsMarch 7, 2023 | msn.comCredit Suisse Maintains Outperform Rating for Stoke Therapeutics: Here's What You Need To KnowMarch 28, 2023 | Tradewins (Ad)Modern Day Options Trading For Beginners!These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. March 6, 2023 | benzinga.comStoke Therapeutics Had $230.2M In Cash, Cash Equivalents, Marketable Securities & Restricted Cash, With Cash Runway Extended To The End Of 2025March 6, 2023 | finance.yahoo.comStoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue EstimatesFebruary 27, 2023 | finance.yahoo.comStoke Therapeutics to Participate at Upcoming March Investor ConferencesFebruary 7, 2023 | finance.yahoo.comStoke Therapeutics to Present at the SVB Securities Global Biopharma ConferenceJanuary 26, 2023 | finance.yahoo.comCompanies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In GrowthJanuary 11, 2023 | markets.businessinsider.comExpert Ratings for Stoke TherapeuticsJanuary 9, 2023 | finance.yahoo.comStoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023January 4, 2023 | finance.yahoo.comStoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 28, 2022 | seekingalpha.comSTOK Stoke Therapeutics, Inc.December 26, 2022 | msn.comStoke Therapeutics Earnings Perspective: Return On Capital EmployedDecember 2, 2022 | finance.yahoo.comStoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual MeetingNovember 29, 2022 | finance.yahoo.comStoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual MeetingNovember 28, 2022 | seekingalpha.comBuy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet SyndromeNovember 15, 2022 | marketwatch.comStoke Therapeutics Down 26% After Reporting STK-001 Data, 3Q ResultsNovember 15, 2022 | seekingalpha.comStoke Therapeutics drops 27% after early data for anti-seizure medicineNovember 15, 2022 | finance.yahoo.comStoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome ProgramNovember 14, 2022 | finance.yahoo.comStoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue EstimatesNovember 10, 2022 | finance.yahoo.comStoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet SyndromeSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address STOK Company Calendar Last Earnings3/06/2023Today3/28/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STOK CUSIPN/A CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees102Year FoundedN/APrice Target and Rating Average Stock Price Forecast$24.57 High Stock Price Forecast$35.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+207.9%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,070,000.00 Net Margins-814.73% Pretax Margin-814.73% Return on Equity-47.38% Return on Assets-35.12% Debt Debt-to-Equity RatioN/A Current Ratio7.77 Quick Ratio7.77 Sales & Book Value Annual Sales$12.40 million Price / Sales28.41 Cash FlowN/A Price / Cash FlowN/A Book Value$4.69 per share Price / Book1.70Miscellaneous Outstanding Shares44,150,000Free Float38,541,000Market Cap$352.32 million OptionableNot Optionable Beta0.42 Key ExecutivesEdward M. KayeChief Executive Officer & DirectorHuw M. NashChief Operating & Business OfficerStephen J. TulipanoChief Financial OfficerBarry S. TichoChief Medical OfficerIsabel AznarezGroup Vice President-Discovery ResearchKey Competitors2seventy bioNASDAQ:TSVTErascaNASDAQ:ERASDesign TherapeuticsNASDAQ:DSGNTango TherapeuticsNASDAQ:TNGXKhosla Ventures AcquisitionNASDAQ:KVSAView All CompetitorsInsiders & InstitutionsAlliancebernstein L.P.Bought 2,900 shares on 2/16/2023Ownership: 0.077%Sphera Funds Management LTD.Bought 31,440 shares on 2/15/2023Ownership: 0.479%State of Wisconsin Investment BoardBought 29,115 shares on 2/15/2023Ownership: 0.112%Alps Advisors Inc.Bought 5,234 shares on 2/15/2023Ownership: 0.068%Jane Street Group LLCBought 3,304 shares on 2/15/2023Ownership: 0.052%View All Insider TransactionsView All Institutional Transactions STOK Stock - Frequently Asked Questions Should I buy or sell Stoke Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STOK shares. View STOK analyst ratings or view top-rated stocks. What is Stoke Therapeutics' stock price forecast for 2023? 7 Wall Street research analysts have issued 1 year price targets for Stoke Therapeutics' stock. Their STOK share price forecasts range from $9.00 to $35.00. On average, they predict the company's share price to reach $24.57 in the next year. This suggests a possible upside of 207.9% from the stock's current price. View analysts price targets for STOK or view top-rated stocks among Wall Street analysts. How have STOK shares performed in 2023? Stoke Therapeutics' stock was trading at $9.23 at the start of the year. Since then, STOK stock has decreased by 13.5% and is now trading at $7.98. View the best growth stocks for 2023 here. When is Stoke Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our STOK earnings forecast. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) posted its quarterly earnings results on Monday, March, 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $0.06. The company had revenue of $3.27 million for the quarter, compared to the consensus estimate of $2.93 million. Stoke Therapeutics had a negative net margin of 814.73% and a negative trailing twelve-month return on equity of 47.38%. What ETFs hold Stoke Therapeutics' stock? ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Direxion mRNA ETF (MSGR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), WisdomTree BioRevolution Fund (WDNA) and Global X Genomics & Biotechnology ETF (GNOM).ALPS Medical Breakthroughs ETF (SBIO). What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA). When did Stoke Therapeutics IPO? (STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Stoke Therapeutics' stock symbol? Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK." Who are Stoke Therapeutics' major shareholders? Stoke Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Morgan Stanley (6.22%), Cowen AND Company LLC (1.90%), Deutsche Bank AG (1.90%), Granahan Investment Management LLC (1.40%), M28 Capital Management LP (1.22%) and Geode Capital Management LLC (1.20%). Insiders that own company stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Robin A Walker and Stephen J Tulipano. View institutional ownership trends. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Stoke Therapeutics' stock price today? One share of STOK stock can currently be purchased for approximately $7.98. How much money does Stoke Therapeutics make? Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $352.32 million and generates $12.40 million in revenue each year. The company earns $-101,070,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. How many employees does Stoke Therapeutics have? The company employs 102 workers across the globe. How can I contact Stoke Therapeutics? Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com. This page (NASDAQ:STOK) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.